From the Department of Family Medicine and Cardiology, Lawson Health Research Institute, University of Western Ontario, Ontario, Canada ; 1 the VA Almazov Federal Center for Heart, Blood and Endocrinology, St Petersburg, Russia ; 2 Global Medical Affairs, Abbott Products Operations, Allschwil, Switzerland ; 3 Evidence Based Communication, Chemin de la Jonchère, Rueil-Malmaison, France ; 4 and the Department of Clinical Pharmacology, Centre Hospitelier Universitaire de Toulouse, INSERM-URM-1048, U de Toulouse III Paul Sabatier, Toulouse, France 5.
J Clin Hypertens (Greenwich). 2012 Feb;14(2):78-84. doi: 10.1111/j.1751-7176.2011.00577.x. Epub 2012 Jan 17.
The Observational Study on Cognitive Function and SBP Reduction (OSCAR) provided opportunities to examine the influence of eprosartan on trends in cognitive performance in a large population of patients with difficult-to-treat hypertension (DTTH). A total of 4649 patients diagnosed retrospectively with DTTH, defined as systolic/diastolic blood pressure (SBP/DBP) ≥140/90 mm Hg despite use of at least 3 antihypertensive drugs during the month preceding the baseline visit comprised the intention-to-treat (ITT) cohort. The patients were given eprosartan-based antihypertension therapy (EBT; 600 mg/d). Blood pressure and cognitive function parameters included significant (P<.001) differences for DTTH vs non-DTTH patients such as older age, body mass index, SBP and pulse pressure (PP), and lower Mini-Mental State Examination (MMSE) score. After EBT for 6 months, SBP/DBP in DTTH was 138.8±12.2/81.9±7.4 (ΔSBP-26±15.7; ΔDBP-11.4±9.8); PP was 57.0±10.8 (ΔPP-14.5±13.8) (all P<.001 vs baseline and non-DTTH group). A total of 2576 patients (87.4%) responded to EBT (ie, SBP <140 mm Hg and/or ΔSBP ≥15 mm Hg, or DBP <90 mm Hg and/or ΔDBP ≥10 mm Hg); 1426 DTTH patients (48.4%) achieved normalized SBP/DBP (ie, SBP <140 mm Hg and DBP <90 mm Hg). ΔPP in DTTH-isolated systolic hypertension (ISH) was -18.0±13.3 mm Hg (P=.003 vs DTTH-systolic-diastolic hypertension). End-of-EBT mean MMSE was 27.5±3.0 (P<.001 vs baseline). Blood pressure responses after EBT coincided with stabilization/improvement of MMSE in this retrospective investigation in DTTH patients. The average improvement in MMSE in DTTH patients was similar to that in non-DTTH patients. EBT effects on PP may be relevant to the evolution of MMSE in DTTH-ISH patients.
观察性认知功能和 SBP 降低研究(OSCAR)提供了机会,以检查依普罗沙坦对治疗困难的高血压(DTTH)患者中认知表现趋势的影响。总共 4649 名患者回顾性诊断为 DTTH,定义为尽管在基线访视前的一个月内使用了至少 3 种降压药物,收缩压/舒张压(SBP/DBP)仍≥140/90 mm Hg,构成了意向治疗(ITT)队列。患者接受依普罗沙坦为基础的降压治疗(EBT;600 mg/d)。血压和认知功能参数包括显著差异(P<.001),例如 DTTH 与非 DTTH 患者的年龄较大、体重指数、SBP 和脉压(PP)以及较低的简易精神状态检查(MMSE)评分。EBT 治疗 6 个月后,DTTH 的 SBP/DBP 为 138.8±12.2/81.9±7.4(ΔSBP-26±15.7;ΔDBP-11.4±9.8);PP 为 57.0±10.8(ΔPP-14.5±13.8)(均 P<.001 与基线和非 DTTH 组相比)。共有 2576 名患者(87.4%)对 EBT 有反应(即 SBP<140 mm Hg 和/或ΔSBP≥15 mm Hg,或 DBP<90 mm Hg 和/或ΔDBP≥10 mm Hg);1426 名 DTTH 患者(48.4%)达到正常 SBP/DBP(即 SBP<140 mm Hg 和 DBP<90 mm Hg)。DTTH 孤立性收缩期高血压(ISH)的ΔPP 为-18.0±13.3 mm Hg(P=.003 与 DTTH-收缩期舒张压高血压相比)。EBT 结束时的平均 MMSE 为 27.5±3.0(P<.001 与基线相比)。在这项对 DTTH 患者的回顾性研究中,EBT 后血压反应与 MMSE 的稳定/改善相一致。DTTH 患者的 MMSE 平均改善与非 DTTH 患者相似。EBT 对 PP 的影响可能与 DTTH-ISH 患者 MMSE 的演变有关。